Post-Operative Pain Management Market Overview
As per MRFR analysis, the Post-Operative Pain Management Market Size was estimated at 42.82 (USD Billion) in 2024. The Post-Operative Pain Management Market Industry is expected to grow from 44.92 (USD Billion) in 2025 to 69.22 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.92% during the forecast period (2025 - 2034). Due to variables, including the prevalence of chronic disease, the rise in surgical procedures, the desire for novel non-opioid analgesics in postoperative pain management therapy, and the growing awareness of palliative care, postoperative pain management approaches are becoming more and more necessary, hence driving the market of post-operative pain management. These are just a few of the market drivers that are driving the market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Bromfenac ophthalmic solution 0.07% was launched in the US by Lupin Ltd, a major player in the pharmaceutical industry, on January 9th this year. The FDA has approved it for use, hence making it ready for purchase on the market. According to the statement released through their listing on the stock exchange, Lupin has obtained an exclusive right of first filing privilege concerning this new product, which gives it a maximum of one hundred and eighty days before allowing anyone else into this business. With estimated yearly sales of $182 million recorded as of November 2023 (according to IQVIA MAT data), Lupin’s bromfenac ophthalmic solution represents huge opportunities in the US market.
On February 2024, Hikma Pharmaceuticals PLC will announce the arrival of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in United States. COMBOGESIC® IV is an intravenous analgesic that lacks narcotics but has acetaminophen 1000mg and ibuprofen NSAID 300mg. It was endorsed as a treatment option for adults by the FDA in October 2013, where an intravenous approach to administration is medically essential: relief of mild-to-moderate pain; moderate-to-severe pain adjunct to opioid analgesics management.
AtriCure announced that it has launched its cryoSPHERE+ cryoablation probe with insulation technology, which reduces freeze times by 25% over AtriCure’s legacy cryoSHPERE® device. The device received FDA clearance in November 2018 and has been utilized in more than sixty thousand cases thus far. The product remains under limited launch status till the end of June when the full rollout will take place across United States borders. It is worth noting that this new probe builds upon proven efficacy and safety metrics achieved with the original cryoSPHERE system comprising of cryoSPHERE compendium, which was launched into the market in November 2018 and has been utilized in excess of 60,000 procedures to date.
Post-Operative Pain Management Market Trends
-
Increased surgeries around the world to propel the market growth
Growing consumer need for painkillers is a major driver of industry expansion. According to National Health data, 100 million procedures are performed annually in the United States. The excessive consumption of painkillers is mostly caused by the rising number of surgeries performed worldwide. Similar to how the prevalence of cancer therapy-related pain is rising, the market is expanding due to an aging and growing geriatric population having various surgeries. Thus, this factor is driving the market CAGR.
Road accidents are predicted to increase over the upcoming years due to an increase in automobiles. Additionally, many people need to take observing traffic laws seriously. Future demand for postoperative pain management is expected to be driven by increased traffic accidents, relative trauma injuries, and pain management after surgeries. If these situations are not handled quickly and effectively, the patient will experience severe agony. Postoperative pain management, however, can help with severe pain and soreness. For such auto accidents, painkillers will be more readily available. These elements are causing the major players to increase their output, ultimately resulting in positive market growth for postoperative pain relief.
The demand for painkiller medications is rising as key stakeholders emphasize the development of abuse-deterrent opioid drugs and launching extended-release non-opioid therapies for post-surgery pain management. Similar to this, greater non-narcotic drug discovery and commercialization and growing awareness of post-surgery pain management support market expansion. Thus, it is anticipated that this aspect will accelerate Post-Operative Pain Management market revenue globally.
Post-Operative Pain Management Market Segment Insights
Post-Operative Pain Management Pain Type Insights
The Market segments of Post-Operative Pain Management, based on pain type, includes acute pain, moderate pain, and severe pain. The severe pain segment held the majority share in 2022 in the Post-Operative Pain Management Market data. Severe pain dominated the market segment as all the major surgeries cause severe pain and doctors recommend pain medication to curb the effect of post-operative pain. This is the reason that the severe pain segment held the major shares and is expected to be a rapidly growing market.
Post-Operative Pain Management Product Insights
The Market segmentation of Post-Operative Pain Management, based on product, includes non-steroidal anti-inflammatory drugs, antiepileptic drugs, and opioids. The opioids segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2025-2034. In North America and Europe, opioids are frequently used for postoperative pain management. However, due to an increase in the use of opioids for non-medical conditions, governing bodies are encouraging doctors to prescribe non-opioid medications, which gives businesses a chance to introduce novel non-opioid medications. Hence, driving the market of post-operative pain management.
Figure 1: Post-Operative Pain Management Market, by Product, 2025 & 2034 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Post-Operative Pain Management Application Insights
The Market data of Post-Operative Pain Management, based on application, include cancer pain, arthritic pain, neuropathic pain, musculoskeletal pain, and migraine. The musculoskeletal pain segment dominated the Post-Operative Pain Management market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2025-2034. Over the past few decades, orthopedic operations have become more commonplace worldwide. Over 175,000 hip replacements and about 500,000 knee replacements are carried out each year worldwide. Therefore, an increase in orthopedic procedures is anticipated to fuel demand for drugs, particularly potent post-surgical pain relievers. Consequently, it is projected that the global market will grow throughout the forecast period.
Post-Operative Pain Management Target Area Insights
The Market data of Post-Operative Pain Management, based on the target area, including back, legs, hands and arms. The legs segment dominated the Post-Operative Pain Management market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2025-2034. This can be attributed to the increase in leg surgeries such as hip replacement, and knee replacement, which is driving the legs segment in the postoperative pain management market.
Post-Operative Pain Management Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Post-Operative Pain Management market is expected to exhibit a significant CAGR growth during the study period. An increase in surgical procedures, a rise in postoperative pain management drug awareness, an increase in product approvals, and a growing emphasis on palliative care primarily support the market's expansion. The Pain Management Index (PMI) was determined for each patient on the first postoperative day. Patients in the US scored higher on the "perception of pain management" subscale of the APS-POQ, and more treatments were rated as acceptable by the PMI. Patient education and levels of pain reduction were predictive of patients' satisfaction with pain management in both countries' patients. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organizations in the market.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Post-Operative Pain Management Market Share By Region 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Post-Operative Pain Management market accounts for the second-largest market share. The rise in open operations is the primary driver of the post-operative pain treatments market in the European Union (EU5). Furthermore, the post-operative pain treatments market in EU5 is being driven by favorable government policies to discover innovative drugs. Moreover, UK market of Post-Operative Pain Management held the largest market share, and the Germany market of Post-Operative Pain Management was the fastest-growing market in the region.
Asia Pacific Post-Operative Pain Management Market is expected to grow at the fastest CAGR from 2025 to 2034. In the Asia Pacific region, several producers of pain medicine are entering into distribution agreements and collaborations and introducing postoperative pain management treatments. Further, the China market of Post-Operative Pain Management held the largest market share, and the India market of Post-Operative Pain Management was the fastest growing market in the region.
Post-Operative Pain Management Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of Post-Operative Pain Management grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the Post-Operative Pain Management industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global Post-Operative Pain Management industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Post-Operative Pain Management industry has provided medicine with some of the most significant benefits. The Post-Operative Pain Management market major player such as Teva Pharmaceutical Industries Ltd., Eli Lilly, Pfizer, Johnson & Johnson, Purdue Pharma, Endo Pharmaceuticals Plc.
An international pharmaceutical corporation with its headquarters in India is Alembic Pharmaceuticals Ltd. It produces pharmaceutical goods, pharmaceutical ingredients, and pharmaceutical intermediates. It is also referred to as the market leader in India's macrolides anti-infective medication category. Pregabalin capsules manufactured by Alembic Pharmaceuticals were given FDA approval in July 2019 to treat neuropathic pain.
An innovative biotechnology business in China called Haihe Biopharma is dedicated to creating, manufacturing, and marketing cutting-edge anti-cancer treatments. Worldwide, people with cancer receive life-saving medications from Haihe. In November 2020, Haihe Pharmaceutical Co. Ltd. and 3D Biomedicine Science & Technology Co. Ltd. signed a contract to outsource the China rights for Haihe's non-opioid analgesic candidates, RMX-1001 and RMX-1002.
Key Companies in the market of Post-Operative Pain Management includes
Post-Operative Pain Management Industry Developments
November 2021: Antibe Therapeutics, Inc. stated that it would share more information about the development strategy for otenaproxesul for acute pain indications in November 2021. Antibe Therapeutics is working on the analgesic and anti-inflammatory medication tenaproxesul. It is a structurally similar NSAID to naproxen. After completing phase I trials in 2015, it was given the go-ahead to begin phase II clinical research for the treatment of osteoarthritis in 2016.
July 2021: The formal release of Maxigesic IV, a cutting-edge non-opioid pain reliever, across significant European markets was announced by Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical business with headquarters in Belgium, in July 2021. (Germany and Austria). A patented, cutting-edge, non-opioid method of treating postoperative pain is called Maxigesic IV. It is a special mixture of an infusion solution containing 300 mg of ibuprofen and 1000 mg of paracetamol.
Post-Operative Pain Management Market Segmentation
Post-Operative Pain Management Pain Type Outlook (USD Billion, 2019-2030)
- Acute Pain
- Moderate Pain
- Severe Pain
Post-Operative Pain Management Products Outlook (USD Billion, 2019-2030)
- Non-Steroidal Anti-Inflammatory Drugs
- Antiepileptic Drugs
- Opioids
Post-Operative Pain Management Application Outlook (USD Billion, 2019-2030)
- Cancer Pain
- Arthritic Pain
- Neuropathic Pain
- Musculoskeletal Pain
- Migraine
Post-Operative Pain Management Target Area Outlook (USD Billion, 2019-2030)
Post-Operative Pain Management Regional Outlook (USD Billion, 2019-2030)
North America
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Attribute/Metric |
Details |
|
Market Size 2024
|
 42.82 (USD Billion)
|
|
Market Size 2025
|
 44.92 (USD Billion)
|
|
Market Size 2034
|
 69.22 (USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
  4.92 % (2025 - 2034)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2034
|
|
Historical Data
|
2020 - 2024
|
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Pain Type, Product, Application, Target Area and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Teva Pharmaceutical Industries Ltd., Eli Lilly, Pfizer, Johnson & Johnson, Purdue Pharma, Endo Pharmaceuticals Plc. |
| Key Market Opportunities |
Non-opioid medication in North American and European markets |
| Key Market Dynamics |
Growing numbers of surgeries to contribute in the growth |
Post-Operative Pain Management Market Highlights:
Frequently Asked Questions (FAQ) :
The Post-Operative Pain Management Market size was valued at USD 69.22 Billion in 2034.
The global market is projected to grow at a CAGR of 4.92% during the forecast period, 2025 - 2034
North America had the largest share in the global market
The key players in the market are Teva Pharmaceutical Industries Ltd., Eli Lilly, Pfizer, Johnson & Johnson, Purdue Pharma, Endo Pharmaceuticals Plc.
The severe pain category dominated the market in 2022.
The musculoskeletal pain had the largest share in the global market.
